21.34 USD
+0.39 (+1.86%)
21.3337 USD
-0.01 (-0.03%)
Overall SRPT gets a fundamental rating of 3 out of 10. We evaluated SRPT against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of SRPT have multiple concerns. SRPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRPT had negative earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
SRPT had negative earnings in 4 of the past 5 years.
SRPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
SRPT has a Return On Assets of -7.77%. This is amongst the best in the industry. SRPT outperforms 86.14% of its industry peers.
SRPT's Return On Equity of -20.57% is amongst the best of the industry. SRPT outperforms 83.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRPT's Gross Margin of 76.25% is amongst the best of the industry. SRPT outperforms 83.71% of its industry peers.
In the last couple of years the Gross Margin of SRPT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
SRPT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
2.2 Solvency
SRPT has an Altman-Z score of -0.01. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
SRPT has a Altman-Z score (-0.01) which is comparable to the rest of the industry.
SRPT has a Debt/Equity ratio of 0.78. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
The Debt to Equity ratio of SRPT (0.78) is worse than 73.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.01 |
ROIC/WACCN/A
WACC7.37%
2.3 Liquidity
SRPT has a Current Ratio of 2.95. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.95, SRPT is doing worse than 63.67% of the companies in the same industry.
SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
SRPT has a worse Quick ratio (1.79) than 77.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for SRPT have decreased strongly by -197.60% in the last year.
SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.15%.
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
The Earnings Per Share is expected to grow by 2.74% on average over the next years.
Based on estimates for the next years, SRPT will show a decrease in Revenue. The Revenue will decrease by -5.76% on average per year.
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y2.74%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.76%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 8.81, the valuation of SRPT can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 98.31% of the companies listed in the same industry.
SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.81 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.1%
EPS Next 3Y2.13%
5. Dividend
5.1 Amount
SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.34
+0.39 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.76%
Inst Owner Change1.91%
Ins Owners4.63%
Ins Owner Change10.75%
Market Cap2.24B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68
Price Target32.03 (50.09%)
Short Float %17.35%
Short Ratio2.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)-2.97%
PT rev (3m)-4.63%
EPS NQ rev (1m)-21.46%
EPS NQ rev (3m)-58.84%
EPS NY rev (1m)1.27%
EPS NY rev (3m)7.8%
Revenue NQ rev (1m)7.56%
Revenue NQ rev (3m)6.8%
Revenue NY rev (1m)0.48%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.81 | ||
| P/S | 0.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.69 | ||
| P/tB | 1.73 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.42
Fwd EY11.36%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 290.01% | ||
| Cap/Sales | 5.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | -0.01 |
F-Score3
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y2.74%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.76%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y11.92%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?
The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -292.84% in the next year.